[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100092968":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":35,"collaborators":37,"id":44,"slug":7,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University of Chicago","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Mary E Strek, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":7},"Vanita Patel, MPH","CONTACT","773-702-1012",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Chicago","Illinois","60637","United States",{"type":25,"coordinates":26},"Point",[27,28],-87.65005,41.85003,{"lat":28,"lon":27},[31,34],{"name":10,"role":15,"phone":32,"phoneExt":7,"email":33},"773-702-3609","mstrek@medicine.bsd.uchicago.edu",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[38,41],{"name":39,"class":40},"Idiopathic Pulmonary Fibrosis Clinical Research Network","NETWORK",{"name":42,"class":43},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100092968",false,"NCT00470327","A Study of the Natural Progression of Interstitial Lung Disease (ILD)","Inclusion Criteria:\n\n* Interstitial lung disease\n\nExclusion Criteria:\n\n* Does not have Interstitial lung disease",true,"ALL","18 Years",{"count":53,"type":54},4000,"ESTIMATED","OBSERVATIONAL","We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the \"phenotypic\" expression of these diseases.",[58,59,60,61],"Interstitial Lung Diseases","Idiopathic Pulmonary Fibrosis","Sarcoidosis","Connective Tissue Disorder",[63,64,60,65],"Interstitial lung diseases","idiopathic pulmonary fibrosis","mRNA and cytokine expression","2026-06-05",{"date":68,"type":69},"2026-06-09","ACTUAL",{"date":71,"type":69},"2005-09",{"date":73,"type":54},"2030-12",{"name":5,"class":6},1]